🧬 AI Discovers a Natural Peptide That Could Rival Ozempic

Researchers at Stanford Medicine have used artificial intelligence to identify a naturally occurring human peptide that suppresses appetite and promotes weight loss in mice—while avoiding the major side effects commonly associated with GLP-1 drugs like Ozempic.

The newly discovered molecule, called BRP, is only 12 amino acids long. Yet in early laboratory experiments, it activated appetite-regulating neurons far more strongly than existing GLP-1 peptides.

Unlike semaglutide, which acts on receptors throughout the brain, gut, pancreas, and other tissues, BRP appears to target primarily the hypothalamus—the brain region responsible for regulating hunger and metabolism. That more focused mechanism may explain why researchers observed no signs of nausea, constipation, anxiety, or muscle loss in the animal studies.

The discovery itself was powered by AI. Stanford’s Peptide Predictor analyzed more than 20,000 human protein-coding genes, searching for hidden biologically active peptides. From 2,683 candidates, researchers narrowed the list to just 100 for laboratory testing—and BRP emerged as the standout.

In obese mice, a single injection reduced food intake by up to 50% within one hour. After two weeks of treatment, the animals lost significant body fat while untreated mice continued gaining weight. The peptide also improved glucose tolerance and insulin sensitivity.

“Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans.” — Dr. Katrin Svensson

The findings are still preclinical, meaning BRP has not yet been tested in humans. But if future clinical trials confirm these results, it could represent a new generation of obesity treatments: delivering GLP-1-like benefits through a much more targeted biological pathway—with fewer unwanted side effects.

📄 Nature (2025)

#AI #Obesity #WeightLoss #Ozempic #Neuroscience #StanfordMedicine #science